Topical and systemic retinoid therapy for cutaneous T-cell lymphoma (Q35622824)

9 August 2017

1 reference

title

Topical and systemic retinoid therapy for cutaneous T-cell lymphoma (English)

1 reference

9 August 2017

1

Werner Kempf

1 reference

9 August 2017

Natascha Kettelhack

2

1 reference

9 August 2017

Madeleine Duvic

series ordinal

3

1 reference

9 August 2017

Günter Burg

series ordinal

4

1 reference

9 August 2017

language of work or name

1 reference

1 December 2003

1 reference

Hematology / Oncology Clinics of North America

9 August 2017

1 reference

9 August 2017

17

1 reference

9 August 2017

1405-1419

1 reference

9 August 2017

6

1 reference

Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Current use and future potential role of retinoids in dermatology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Retinoids in cancer prevention and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Antiproliferative activity of retinoids, interferon α and their combination in five human transformed cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

The role of retinoids and retinoic acid receptors in normal hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Retinoic acid-induced apoptotic pathway in T-cell lymphoma: Identification of four groups of genes with differential biological functions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, a beta 2 integrin critically involved in T-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Retinoid regulation of interleukin-2 receptors on human T-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Effect of retinoids on natural killer cell activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Retinoic acid resistance in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Isotretinoin in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

The effect of isotretinoin in six patients with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Combined modality therapy for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Treatment of cutaneous lymphoma with etretinate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Treatment of cutaneous T-cell lymphoma with a new aromatic retinoid (Ro 10-9359)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

A case of mycosis fungoides treated with etretinate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Retinoids in cutaneous T cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Roferon-A in combination with Tigason in cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Interferon-alpha (INF-alpha) and etretinate in the treatment of mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Biological modifiers (etretinate (changed from etetrinate) and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Follicular mucinosis associated with early stage cutaneous T-cell lymphoma: successful treatment with interferon alpha-2b and acitretin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Sarcoid-like granuloma following prolonged etretinate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

1 reference

7 January 2021

The treatment of cutaneous T-cell lymphoma with a novel retinoid.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Optimizing bexarotene therapy for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Treatment of cutaneous T cell lymphoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Central hypothyroidism associated with retinoid X receptor-selective ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Vitamin D analogs in cutaneous malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Treatment of cutaneous T-cell lymphoma by retinoids and calcitriol

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Cutaneous T-cell lymphoma and calcitriol and isotretinoin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Treatment of cutaneous T-cell lymphoma with alitretinoin gel.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Lymphomatoid papulosis--treatment with recombinant interferon alfa-2a and etretinate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

13-cis-retinoic acid induces cellular differentiation and durable remission in refractory cutaneous ki-1 lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: Special emphasis on the tumor response to 13-Cis retinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Stage IV CD30+ anaplastic large cell lymphoma: response to acitretin and interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Bexarotene is a new treatment option for lymphomatoid papulosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

Initial clinical trial of a selective retinoid X receptor ligand, LGD1069

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900107-2

7 January 2021

10.1016/S0889-8588(03)00107-2

Identifiers

DOI

1 reference

9 August 2017

1 reference